ScripThe end of 2023 is proving no different from the end of any other year, with venture capital firms and biopharmaceutical companies closing out a flurry of new VC funds and financings before December d
ScripEvolveImmune Therapeutics, Inc. is leveraging its proprietary EVOLVE platform to develop three-pronged T cell engagers that could reduce immune evasion by tumor cells via CD2 activation, with an init